1341 PharmaBio Delegate Booklet

1341 PharmaBio Delegate Booklet 28/11/07 14:41 Page 1 

FT GLOBAL CONFERENCES & EVENTS 

FT GLOBAL 

PHARMACEUTICAL 

AND BIOTECHNOLOGY 

CONFERENCE 2007 

Convergence, Collaboration, and Customers: 

Driving Innovation, Accelerating Growth 

3 & 4 December 2007 

The Cumberland, London 

www.ftpharmabiotech.com 

In association with 

Sponsors


General information 

DRINKS RECEPTION 

A drinks reception will take place in the Ocean suite foyer from 17:00 on 3 December 2007. 

FEEDBACK FORMS 

These will be distributed towards the end of the first day of the event. We would very much appreciate your completed 

form being handed to the registration desk on departure from the conference. 

MOBILE PHONES 

As a courtesy to other delegates, please ensure your mobile phone is switched off while in the Conference room. 

SECURITY 

For security reasons it is important that you wear your conference badge at all times. 

INTERNET ACCESS 

Internet pods are located in the coffee break area for delegates to access. Should you wish to have wireless internet for 

your laptop then please purchase an access code from the hotel info point in the coffee break area. 

FIRE PROCEDURE 

All delegates need to be aware of the procedures to be followed in the event of fire or if the fire alarm is sounded. 

Please familiarise yourself with the nearest emergency exits. If you discover a fire, immediately operate the nearest 

break glass call point, and notify a member of the conference or hotel staff. On hearing the alarm you should 

proceed immediately to the assembly point located on the hotel forecourt. 

SPEAKER PRESENTATIONS AND AUDIO DOWNLOADS 

These will be available to download from the FT Conferences website from Monday 17 December. 

The access details are: www.ftconferences.com/pharmabiotech 

Username/email address: pharma@ft.com 

Password: papers 

Please note that only presentations and audio downloads for which we have permission to publish will be available and 

that these are subject to FT copyright rules. These can be viewed at www.ft.com


Welcome 

Dear Guest 

It is our great pleasure to welcome you to the FT Global Pharmaceutical and Biotechnology Conference here at 

the Cumberland Hotel in London. 

As the leading annual event in the industry calendar, the conference will provide you with the opportunity to gain 

critical insights into the foremost trends and issues shaping your industry, and through the many participatory 

panels and roundtables, will provide an unrivalled opportunity to network and share experience with your peers. 

The theme of this year’s conference is “Convergence, Collaboration and Customers”. In an era when increased 

competition and globalisation are the new realities of business, pharmaceutical and biotechnology companies are 

less likely to achieve future growth organically, and networking and collaborations of all kinds – through licensing and 

acquisitions, and through collaborations within and across the life sciences, medical devices and healthcare industry 

are set to become ubiquitous. 

The big questions we will be asking each of our speakers are: 

• How will the undying trends of convergence, collaboration and customer orientation change the landscape of the 

life sciences and healthcare industries? 

• How is value creation shifting across the industry value chain, and how can the opportunities for innovation be 

optimised? 

We hope that you will enjoy what promises to be an excellent event and that you will join us for the drinks reception 

this evening. 

Yours, 

Jayne Van Hoen 

Director, Global Conferences & Events 

Financial Times 

–– 3 ––


Monday 3 December 2007 

08:00 Registration and Coffee 

09:00 CHAIR’S OPENING REMARKS 

Mr Andrew Jack, Pharmaceutical Correspondent, Financial Times 

New Avenues for Innovation in the Global 

Pharmaceutical and Biotechnology Industries 

Convergence: Driving Innovation, Accelerating Growth 

• How will convergence transform the structure of the global life 

sciences and healthcare industries? How is value creation shifting 

across all areas of the life sciences and healthcare value chain? 

• How can opportunities for innovation through convergence be 

optimised? 

• Pharma and biotech: converging or diverging futures? 

Mr Robert Wessman, President and CEO, Actavis Group 

Dr Lisa Drakeman, President and CEO, Genmab 

Mr Angus Russell, Chief Financial Officer, Shire plc 

Questions and Answers 

10:00 Convergence in Practice: Devices, Drugs and IT 

• Winners and losers in convergence: how can biotech, device and 

diagnostic companies ensure that they are equal partners in the 

convergence game? 

• Implications for industry structure: to what extent will convergence 

lead to the evolution of pharma and biotech companies as broader 

‘healthcare companies’? 

• Making convergence work: overcoming practical barriers to crosssector 

convergence (e.g. managing expectations regarding timelines 

for R&D) 

Dr Steven Powell, Chief Executive Officer, Plethora Solutions Limited 

Mr Simon Hammett, UK Life Sciences and Health Care Practice Leader, 

Deloitte 


10:30 Leveraging Emerging Markets for Innovation and 

Revenue Growth 

10:45 Coffee 

Mr Bob Go, Global Managing Director, Life Sciences and Health Care, 

Deloitte 


11:15 Waking to the Century of Networked Pharma 

The Strategic Imperative of Collaboration, Partnerships 

and Consolidation 

• The implications of the networked pharma model? How is 

networking changing the fundamentals of the industry? 

• Key to successful partnerships: overcoming organisational and 

cultural challenges 

Dr Louise Makin, Chief Executive Officer, BTG plc 

Mr Dan Zabrowski, Global Head Pharma Partnering, Roche 


11:45 Public-Private Partnerships 

• How can currently fragmented public and private R&D efforts be 

brought together more efficiently to create truly life saving innovation? 

• What is the opportunity for pharmaceutical and biotechnology 

companies in PPPs e.g. creating commercial spin-offs for 

pharmaceutical and biotechnology, and providing new funding, 

licencing and marketing opportunities for the biotech companies? 

• How do PPPs work, and what is the key to their success? How can 

the scope and effectiveness be improved? 

Dr Jean-Pierre Paccaud, Director of Business Development, 

Drugs for Neglected Diseases initiative (DNDi) 

Dr Lynn Marks, Senior Vice President, Infectious Diseases Medicine 

Development Centre, GlaxoSmithKline 


–– 4 –– 

12:15 Panel: Delivering Innovation through Effective Licensing 

– Next Frontiers 

• Examining the opportunities and pitfalls of licensing in Asia and 

emerging markets: does licensing in emerging markets hold the key 

to success of stand-alone biotech? 

• Strategies for growth: licensing vs. M&A 

• Emerging licensing structures and deal terms-what are the 

emerging innovations? 

Dr Geoffrey Guy, Executive Chairman, GW Pharmaceuticals Plc 

Dr Simon Moroney, Chief Executive Officer, MorphoSys AG 

Mr John Mayo CBE, Managing General Partner, Celtic Pharma 

12:45 Panel: Mergers and Acquisitions – Reshaping the 

Pharma Future? 

• How will the current round of M&A transform the landscape of the 

industry? 

• What are the broader implications of pharma’s current appetite for 

biotech acquisitions for innovation in the industry? 

• What are the particular challenges relating to integrating biotech 

acquisitions for pharmaceutical companies? e.g. keeping the culture 

of innovation alive? 

• Assessing the implications of the rise of acquisitive emerging market 

pharma companies as international players 

Mr Shinichi Tamura, President and CEO, Sosei Group Corporation 

Mr John Goddard, Senior Vice President, Strategic Planning and 

Business Development, AstraZeneca plc 

Ms Kate Bingham, Managing Partner, SV Life Sciences 

13:15 Networking Lunch 

14:30 CHAIR 

Mr Martyn Postle, Director and Founder, 

Cambridge Healthcare and Biotech Ltd 

Leveraging Customer Collaboration 

14:40 New Approaches to Collaboration with Government 

Mr Meindert Boysen, Associate Director – Single Technology 

Appraisals, National Institute of Clinical Excellence (NICE) 

15:00 Patients: Riding the Rising Tide of Healthcare 

Consumerism 

15:30 Coffee 

Mr Simon Denegri, Chief Executive, 

Association of Medical Research Charities (AMRC) 


16:00 Innovation and the Global Pharmaceutical, 

Biotech and Medical Devices Industries 

Exploring the Vital Link Between Pricing and Innovation: 

New Business Pricing Models and Reimbursement 

Dr Panos Kanavos, Lecturer, International Health Policy, 

London School of Economics 

Ms Ann Pope, Director, Markets and Projects-Goods, 

Office of Fair Trading (OFT) 


16:30 Funding for Innovation 

Dr Andy Richards, Early Stage Biotechnology Investor 

Mr Ted Bianco, Director of Technology Transfer, Wellcome Trust 


17:00 Networking Drinks Reception 

The organisers reserve the right to alter the programme and speakers as may be necessary. 

© Financial Times Limited 2007.


Tuesday 4 December 2007 

08:30 Registration and Coffee 

09:00 CHAIR’S OPENING REMARKS 

Ms Salamander Davoudi, Biotechnology Correspondent, Financial Times 

09:05 Keynote Address 

Mr Christian Siebert, DG Enterprise and Industry, European Commission 


09:40 Revisiting the Fundamentals of Innovation 

• Change as an innovation catalyst 

• Organisational and cultural challenges in innovation: governance and people strategy 

• Encouraging radical innovation to occur and be accepted 

• Innovation in life sciences: transforming R&D 

Mr Rajiv Narang, Founder and CEO, Erehwon Innovation Consulting PvT Ltd 

Dr Emilio Emini, Executive Vice President, Vaccines Research and Development, Wyeth Pharmaceuticals 


10:30 Innovation Strategies: is Big Pharma too Big and Biotech too Small to Innovate? 

Mr Luciano Conde, Chief Executive Operating Officer, Almirall 


10:45 Driving Innovation: Transforming Patient Safety with Authentication 

Mr Gary Noon,CEO,Aegate 


11:00 Networking Coffee Break 

11:30 Roundtable Sessions 

The Impact of the Emerging Biopharma Model on the Supply Chain Hosted by 

• The world of biologics: higher variability, lower yield, lower predictability 

• Examining supply chain implications of the migration from blockbuster drugs to targeted pharma solutions 

• New models in demand forecasting 

• New supply chain models: design for flexibility and selective outsourcing 

Mr Reynold W (Pete) Mooney, Global Leader, Life Sciences Consulting, Deloitte Consulting LLP 

Innovation Strategies: Creating an Environment that can Deliver Innovation Hosted by 

• The importance of focusing on a franchise to drive growth 

• The relevance and importance of early collaboration with other departments 

• The importance of human capital: focus and skill 

• Securing and developing effective partnership agreements 

• Extending the product life cycle vs development of blockbuster therapies 

Mr Luciano Conde, Chief Executive Operating Officer, Almirall 

Healthcare Innovation: a Look at the Current and Future Role of Authentication in Patient Safety Hosted by 

• Examining best practice examples across the globe 

• Explore where an authentication service currently used in the healthcare industry might fit in the future, i.e. hospitals, specialist 

clinics or doctor surgeries 

• The opportunities authentication technology offers the market, particularly in terms of improved communication channels 

• Examine further opportunities for authentication in the pharmaceutical industry 

Mr Brian Thornley,COO,Aegate 

Aiming for Global Launch Excellence: Where to Focus for Success? Hosted by 

• Engage all decision makers and expand markets 

• Adapt locally to new models 

• Align organisation, bridge silos 

• Optimise and adjust within the six month launch window 

Mr John D MacCarthy, Vice President, Client Thought Leadership, IMS Health ® 

12:45 Networking Lunch 

13:30 Roundtables (continued) 

14:30 Pharma-Bio Futures 

In this concluding session of the conference, the panel will share their views on the major trends and future challenges facing the industry, and the likely impact 

of convergence, collaboration and customers on the industry’s innovation and growth strategies. 

Mr Nick Lowcock, Managing Director, Warburg Pincus 

Mr Ton Gardeniers, Global Head of Healthcare, ABN Amro 

15:00 Close of conference 

–– 5 ––


Speakers 

Mr Ted Bianco 

Director of Technology Transfer 

Wellcome Trust 

Ted Bianco is Director of Technology Transfer at the Wellcome Trust with 

responsibility for the promotion of early stage R&D through translational 

research funding and the management of intellectual property arising from 

Wellcome Trust-sponsored research. Ted has 25 years experience in biomedical 

research, specialising in tropical medicine and infectious disease. He obtained 

his PhD at the London School of Hygiene and Tropical Medicine and 

subsequently worked at the Walter and Eliza Hall Institute in Melbourne, Imperial 

College of Science, Technology and Medicine in London and the Liverpool School 

of Tropical Medicine, where he was the Walter Myers Professor of Parasitology. 

He joined the Wellcome Trust in 1999 as head of the Centres and Major Initiatives 

department. Mr Bianco is an honourary professor of the Liverpool School. 

Ms Kate Bingham 

Managing Partner 

SV Life Sciences 

Kate Bingham joined SV Life Sciences in 1991 and currently serves or has 

served on the boards of Affibody, Dynogen, Hexagen, Ingenium, LeukoSite, 

MedNova, Metris, Nexan, PowderMed, and Trine Pharmaceuticals. She has 

also been responsible for investments in Alantos, Auxilium, ESBATech, 

Genosis, Gyros, Kinetix, KuDOS, Lorantis and Micromet. Prior to joining SVLS, 

Ms Bingham worked in business development for Vertex Pharmaceuticals, a 

biotechnology company in Cambridge, MA and at Monitor Company, a 

strategy consulting firm. She has a masters degree in Biochemistry from 

Oxford University and graduated from Harvard Business School with an MBA. 

Mr Luciano Conde 

Chief Executive Operating Officer 

Almirall 

Luciano Conde is Chief Operating Officer at Almirall. He is also Deputy Chairman 

of the Management Board, Member of the Board of Directors, Co-chairman of 

the Pipeline Committee and President of the Operating Committee. Mr Conde 

joined Almirall in 1996 as Senior Commercial Director. He was promoted to his 

current position in 2002. Mr Conde has worked extensively in the 

pharmaceutical industry since 1981. Prior to joining Almirall, his most recent 

position was with Pharmacia where, between 1993 and 1995, he was Executive 

Vice President, Director Open Care Manager, Site manager for Madrid 

Manufacturing and Commercial location, and a Member of the Management 

Executive Committee. He has also previously worked at Farmitalia Antibióticos 

Farma, Roche Products (Pharma Division), Roche Products (Diagnostics) in 

Spain and Insalud (the Spanish national institute for health). 

Mr Conde has a Pharmacy degree from the University Complutense (Madrid). 

He has also undertaken postgraduate studies in product marketing and sales, 

management, pharmaceutical marketing, and strategy for successful mergers 

and acquisitions. 

–– 6 –– 

Ms Salamander Davoudi 

Biotechnology Correspondent 


Salamander Davoudi joined the Financial Times as a journalist in 2003. She has 

worked as a reporter covering the UK and European equity markets. In 2004 

she moved to the Washington bureau where she was responsible for covering 

US defence policy at the Pentagon. On her return to London she joined the UK 

companies team specialising in the support services sector. She has been the 

biotechnology correspondent since 2006. She graduated from Edinburgh 

University and completed her Masters at Georgetown University in the US. 

Mr Simon Denegri 

Chief Executive 

Association of Medical Research Charities 

Simon Denegri joined AMRC as its Chief Executive in February 2006. 

Previously, Mr Denegri had been Director of Corporate Communications at the 

Royal College of Physicians of London from 2003. He was Assistant Chief 

Executive at the Alzheimer’s Society (UK) from 2002 to 2003 and its Head of 

Public Affairs from 1992 until 1997. In the intervening period he was Corporate 

and Financial PR Manager at Procter & Gamble in the United States and then 

Director of Communications at the Sainsbury Centre for Mental Health 

(SCMH). He has written and spoken extensively on issues concerning health 

and healthcare policy and practice. 

Dr Lisa Drakeman 

President and Chief Executive Officer 

Genmab 

Dr Drakeman has served as Genmab’s President and Chief Executive Officer 

since the company’s inception. Dr Drakeman has over eighteen years of 

experience working in the biotechnology industry, including establishing 

corporate partnerships with major pharmaceutical companies, managing 

clinical trials of monoclonal antibody-based products and developing 

government programs for financing biotechnology research. In her position as 

Chief Executive Officer, she has also set a number of financing records, 

including the largest private investment ever for a biotech company, the largest 

IPO ever by a European biotech company and the largest licensing transaction 

worldwide. Under Dr Drakeman’s leadership, Genmab received the James D 

Watson Helix Award as the best international biotechnology company in 2004 

for leadership in scientific innovation, company growth and corporate 

citizenship. She has received a number of awards and honours including being 

named “Advocate of the Year” by the Biotechnology Industry Organisation in 

1995, “Industry Woman of the Year” by the Biotechnology Council of New Jersey 

in 1996, being inducted in the New Jersey High Technology Hall of Fame in 

2000 and one of “New Jersey’s Best 50 Women in Business" by NJBIZ in 2007. 

Dr Drakeman serves on board of the Biotechnology Council of New Jersey. She 

previously served as a member of the faculty and administration at Princeton 

University and as Senior Vice President, Head of Business Development for 

Medarex, Inc. She received a B.A. degree, from Mount Holyoke College, M.A., 

from Rutgers University, and M.A. and PhD, from Princeton University.


Dr Emilio Emini 

Executive Vice President, Vaccines Research 

and Development, Wyeth Pharmaceuticals 

Dr Emilio Emini, is the executive vice president for Vaccine Research and 

Development at Wyeth Pharmaceuticals, a position he has held since 2005. 

He leads an organisation of approximately 600 scientists and professionals 

responsible for research and development for Wyeth vaccines. 

Prior to joining Wyeth, Dr Emini was the senior vice president for vaccine 

development at the International AIDS Vaccine Initiative (IAVI). He developed 

his vaccine expertise from 1983 to 2004 at the Merck Research Laboratories, 

serving in eight positions. Dr Emini began his Merck tenure as a senior research 

microbiologist, later assuming the directorship of HIV biology and immunology, 

serving as the executive director of the Department of Antiviral Research and 

then becoming the senior vice president of vaccine and biologics research. 

Since 2004, Dr Emini has chaired the National Institutes of Health (NIH) Vaccine 

Development Resources Committee and has served as a member if the NIH 

AIDS Vaccine Research Working Group. He is a fellow of the American Academy 

of Microbiology and a member of seven scientific societies, including the New 

York Academy of Sciences, the American Association for the Advancement of 

Science, Sigma Xi and International Society for Antiviral Research. 

He is a lecturer at three universities, educating students on medical 

microbiology, graduate virology, viral pathogenesis at Hahnemann University, 

on graduate virology at the University of Pennsylvania, and on undergraduate 

virology at Princeton University. 

Mr Ton Gardeniers 

Global Head of Healthcare 

ABN Amro 

Ton Gardeniers is the Global Head of Healthcare at ABN AMRO for the group’s 

global investment banking and corporate banking business and its various 

sub-sectors. He joined ABN AMRO in 2000 and prior to that he was a Senior 

Investment Director with Gilde Investment Management in the Netherlands, 

responsible for the establishment of several biotech related venture capital 

funds. He was also Head of Corporate Finance for Rabobank North America 

based out of New York. Ton spent 14 years at JP Morgan Europe and New York, 

where he was involved in a variety of business lines including Corporate 

Finance and Capital Markets. 

–– 7 –– 

Mr Bob Go 

Global Managing Director, Life Sciences 

and Health Care, Deloitte 

Bob Go is Deloitte’s Global Leader for Industries and the Global Managing 

Director for Life Sciences and Health Care. In his nearly 30 years with Deloitte, 

Mr Go has worked with Boards of Directors and senior management of several 

hundred companies on issues of corporate strategy, governance, Organisation, 

and business transformation. 

In addition to his work with clients, he has also served as a member of the 

Deloitte & Touche USA LLP Board of Directors, including a period as its Vice 

Chairman, and the Deloitte Consulting Management Committee. Mr Go 

currently participates as a guest member of the Board of Deloitte & Touche 

Canada. Bob has spoken at Deloitte and external forums, including 

presentations at the World Economic Forum on issues concerning Life 

Sciences, innovation and future scenarios for China and India. He has an MBA 

from the University of Santa Clara. 

Mr John Goddard 

Senior Vice President, Strategic Planning and 

Business Development, AstraZeneca plc 

John Goddard was appointed Senior Vice President and Head of Strategic 

Planning and Business Development for AstraZeneca in May 2006 and is 

based in London. In addition, Mr Goddard is Chairman of Aptium Healthcare 

Inc, a wholly owned subsidiary based in Los Angeles, which manages the 

provision of outpatient cancer care and Chairman of AstraTech another wholly 

owned subsidiary, which develops, manufactures and markets advanced 

healthcare devices for single use and dental implants. 

Prior to moving to London, Mr Goddard was Senior Vice President and Chief 

Financial Officer for AstraZeneca in the United States and was responsible for 

all AstraZeneca Group finance matters in North America. 

He began his career with Bell and Howell Limited, Rank Xerox and Spicer and 

Pegler in the UK. He joined ICI in 1985 and worked in London until 1988, when 

he was appointed finance director for ICI Japan, based in Tokyo. In 1991, he 

became chief financial officer for ICI Asia Pacific based in Singapore, and was 

appointed finance director for Zeneca Pharmaceuticals in 1993 back in the UK, 

a position he held through 1998 when he moved to the US.


Speakers 

Dr Geoffrey Guy 

Executive Chairman 

GW Pharmaceuticals Plc 

Dr Guy has over twenty years experience in pharmaceutical development 

covering new chemical entities, biotechnology products, plant-based 

medicines, controlled drugs and drug delivery systems. Dr Guy has been the 

physician in charge of over 200 clinical studies including first dose in man, 

pharmacokinetics, pharmacodynamics, dose-ranging, controlled clinical trials 

and large scale multi-centred studies and clinical surveys. 

In 1981 Dr Guy moved into the pharmaceutical sector and joined Pierre Fabre 

Laboratories in Castres, France where he subsequently became UK Clinical 

Trials Co-ordinator. In 1984 Dr Guy moved to become first Director of Clinical 

Development and then Assistant Medical Director of Napp Laboratories in 

Cambridge. Between 1983 and 1985 Dr Guy founded and was a Partner in 

Datalink Biomedical, a company established to exploit a computerised digital 

lung function machine. 

In 1985 Dr Guy founded the drug delivery company Ethical Holdings plc, of 

which he was Chief Executive Officer and Chairman (from 1991), and led the 

company to its NASDAQ flotation in 1993 before leaving in 1997. Dr Guy received 

3i’s “Venturer of the Year” award in the Science and technology category. 

Through Ethical he also pursued a policy of investment in other 

pharmaceutical opportunities which led to the founding of Phytopharm plc, 

the plant medicines company listed on the UK stock exchange. Dr Guy was, 

until 1997, Chairman of Phytopharm the objective of which was to develop 

plant-based medicines derived from traditional Chinese medicine. 

Ethical also invested in the jet injector company Antares Pharma Inc (formerly 

Medi-Ject Corporation) in 1994 and Dr Guy was a Director of the company 

from November 1993 until January 2001. 

In 1997 the Home Office granted Dr Guy licenses to cultivate, possess and 

supply cannabis for research purposes and in 1998 GW Pharmaceuticals Plc 

was established through which to operate these licenses. The objective of GW 

was, and remains, to develop a portfolio of non-smoked, prescription 

cannabis-based medicines and the Company has been carrying out a number 

of Phase I, II and III clinical trials investigating the use of these medicines in 

multiple sclerosis, neuropathic pain, spinal cord injury and cancer pain. 

Simon Hammett 

UK Life Sciences and Health Care Practice Leader 

Deloitte 

Simon Hammett is a Partner in the Consulting practice at Deloitte. He is a 

senior partner within our UK Strategy practice and also leads the EMEA 

Growth and Innovation team. He focuses on Pharmaceuticals and 

Manufacturing and has worked extensively with leading global pharmaceutical 

and medical companies including: GlaxoSmithKline, Pfizer, British Oxygen 

Company and Roche. 

Mr Hammett is very active in client service and focuses on competitive 

strategy development, strategy implementation including enterprise-wide 

transformation, and CRM/sell-side solutions. He joined the firm from business 

school in 1993 with 6 years’ previous management experience. His experience 

included research management, new product development, new ventures, 

technical sales and enterprise strategy. 

–– 8 –– 

Mr Andrew Jack 

Pharmaceutical Correspondent 


Andrew Jack is a journalist with the Financial Times, currently based in 

London. He joined the newspaper in 1990, and worked as a correspondent in 

London, Paris and Moscow. Since 2005, he has covered pharmaceuticals and 

healthcare. He is author of the books Inside Putin’s Russia (Granta/Oxford 

University Press, 2005) and The French Exception (Profile Books/Editions 

Odile Jacob, 2001). He graduated from Cambridge University, studied at 

Harvard University and worked for New York City Government and as a 

freelance consultant and writer before joining the FT. 

Dr Panos Kanavos 

Lecturer, International Healthcare Policy 

London School of Economics 

Panos Kanavos is Senior Lecturer in International Health Policy in the Department 

of Social Policy, Merck Fellow in Pharmaceutical Economics and Head of the 

Medical Technology Research Unit at LSE Health. He is also Visiting Professor 

at the University of Lausanne. He has acted as advisor to a number of 

international governmental and non-governmental organisations, including the 

World Bank, the World Health Organisation and the Organisation for Economic 

Co-operation and Development, the American Association for Retired Persons 

and Ministries of Health in over 21 transition and developing countries. He is 

currently participating in the European Pharmaceutical Forum as advisor to 

the European Commission. His research interests comprise comparative 

health policy and health care reform; pharmaceutical economics and policy; 

quality in health care; and the socio-economic determinants of health. 

Mr Nick Lowcock 

Managing Director 

Warburg Pincus 

Nicholas J. Lowcock leads the firm’s healthcare investing activities in Europe. 

Mr Lowcock was with the Boston Consulting Group before he joined Warburg 

Pincus in 1994. He previously worked in the pharmaceutical industry in the 

United Kingdom. Mr Lowcock received a B.A. (first class) in experimental 

psychology from Oxford University and an M.B.A. with distinction from The 

Wharton School at the University of Pennsylvania. He is a member of the 

board of trustees of Project Hope UK, a charity devoted to improving 

healthcare in developing nations. Mr Lowcock is a director of Archimedes, 

Eurand, Euromedic and ProStrakan.


Dr Louise Makin 

Chief Executive Officer 

BTG plc 

Dr Louise Makin is currently Chief Executive Officer of BTG plc, which develops 

novel pharmaceuticals and other medical technologies. She was appointed 

Chief Executive Officer in October 2004 and has led the turnaround and 

strategic repositioning of the company. Previously, Dr Makin was President of 

the Biopharmaceuticals Division of Baxter Healthcare Europe, after having 

joined Baxter in 2000 as Vice President, Strategy & Business Development 

Europe. Prior to Baxter, she spent 13 years with ICI and English China Clay. 

Dr Makin holds an MA in Natural Sciences, a PhD in Metallurgy from the 

University of Cambridge, and an MBA. She is also a Non Executive Director on 

the Board of Premier Foods plc, Chairman of the Advisory Board of Lancaster 

University Business School and a Trustee of the Engineering Development Trust. 

Dr Lynn Marks 

Senior Vice President, Infectious Diseases Medicine 

Development Centre, GlaxoSmithKline 

Dr Marks received his medical degree from the University of South Alabama 

College of Medicine and is Board Certified in Internal Medicine and 

Infectious Diseases. 

He joined SmithKline Beecham in 1993 as Associate Director and later 

Director, Anti-infectives Clinical Research, Development, and Medical Affairs. 

He then moved to the Consumer Healthcare Division where he held the 

positions of Worldwide Medical Director, Rx to OTC Switch and then, Vice 

President and Director, Worldwide Medical, Regulatory, and Toxicology. 

Later he returned to Pharma as, Vice President, Global Commercial Strategy, 

Infectious Diseases and subsequently became Senior Vice President, 

Infectious Diseases, Medicine Development Centre. Prior to joining industry, Dr 

Marks was with the University of South Alabama College of Medicine, where 

he held the positions of Assistant Professor of Medicine in the Division of 

Infectious Diseases and Adjunct Assistant Professor in the Department of 

Microbiology and Immunology as well as the Department of Pharmacology. 

His NIH supported research centred on the molecular genetics of Rickettsia. 

–– 9 –– 

Mr John Mayo CBE 

Managing General Partner 

Celtic Pharma 

John Mayo graduated in Economics from Loughborough University and 

qualified as a Chartered Accountant. As an investment banker in the eighties 

and early nineties, John Mayo advised among others on the spin-off of Zeneca 

Group plc by ICI plc; the privatisation of Irish Life ($750 million) and the IPO of 

Wellcome plc ($1.5 billion). In 1997, he initiated the merger between Zeneca 

and Astra, and in September 1997 John left to join The General Electric 

Company plc as Finance Director. 

He has founded and grown several businesses including Beehive Capital LLP, 

and Salisbury Associates. During the last 10 years he has served as a 

non-executive director on the boards of the following public companies: 

Schlumberger, Alstom, Newcastle United, and Pentland. He has also served on 

the following UK public bodies: The Takeover Panel; The Confederation of 

British Industry’s Companies Committee; Her Majesty’s Treasury Public 

Sector Productivity Panel; and the FTSE Policy Committee. In 1999, John Mayo 

was made a Commander of the British Empire (CBE), in recognition of his 

services to British industry. John Mayo is a founder of Celtic Pharma, a global 

private equity firm focused on the pharmaceutical industry. He is a UK citizen 

and is based in London. 

Mr John D MacCarthy 

Vice President, Client Thought Leadership 

IMS Health ® 

Mr MacCarthy is Vice President, Client Thought Leadership at IMS Health and 

is responsible for spearheading the development of the company's thought 

leadership based approach to customer engagement globally. He works 

extensively with clients in both the US and Europe. 

His background includes over 20 years experience in the pharmaceutical 

industry gained in a career that began at Beecham Research Laboratories 

(now part of GSK) in 1977. He later joined Pharmacia UK in 1984 where he 

spent a number of years in roles in Sales, Marketing Management and 

Corporate Development. In 1995, John was appointed V.P. Strategy for 

Pharmacia & Upjohn Europe, based in Paris. He was a member of the UK 

integration teams following the mergers of Kabi Vitrum with Pharmacia and of 

Kabi Pharmacia with Farmitalia Carlo Erba, and a member of the global 

integration team during the Pharmacia and Upjohn merger. 

Since joining IMS Health in 1998, Mr MacCarthy has also been responsible for 

creating the sales force effectiveness suite of offerings in Europe and has been 

a major contributor to the development of the continuum of information, 

analytics and consulting services in the region. 

He has supported client management teams in the USA and most major 

European markets to develop action plans to drive measurable improvement 

in the performance of key brands. In one case, in a project covering over 10 

countries, an improvement in brand performance of over $40m was achieved. 

Mr MacCarthy holds a Masters Degree in Business Administration and a 

Bachelors degree in Applied Chemistry.


Speakers 

Mr Reynold W (Pete) Mooney 

Global Leader, Life Sciences Consulting 

Deloitte Consulting LLP 

Mr Mooney leads Deloitte’s U.S. life sciences consulting practice. A strategy 

and operations practitioner with over twenty two years of consulting 

experience, he has assisted senior executives from many cultures address the 

difficult, complex business issues associated with value creation through 

growth, asset effectiveness and cost containment. 

A long time European resident who has recently moved to the US, most of Mr 

Mooney’s experience has been international. He has conducted major 

consulting engagements in North and South America, Europe and Asia for 

pharmaceuticals companies, biotechs, medical device manufacturers, and 

specialty and commodity chemicals manufacturers. His clients include 

companies such as Roche, Novartis, Amgen, Applied Bio, Stryker, Bayer, 

Johnson & Johnson, Pfizer, Akzo Nobel, Sanofi-Aventis, GlaxoSmithKline, DSM, 

Broken Hill Proprietary and the Government of Argentina. 

Mr Mooney has held a number of leadership roles within the firm. He has 

served as the Chief Executive Officer of Deloitte Consulting Nederland B.V., as 

the firm’s Industry Practice Director, Europe Manufacturing and as a member 

of the firm’s European Management Committee. 

Beginning his professional career with USX Corporation prior to joining Touche 

Ross & Co., Mr Mooney then worked for Braxton Associates, a global strategy 

consulting firm, for eight years before rejoining the merged Deloitte & Touche. 

He has a B.A. in History and Economics from Washington & Jefferson College 

and an M.B.A. from the Katz School, University of Pittsburgh. 

Dr Simon Moroney 


MorphoSys AG 

Dr Simon Moroney is one of MorphoSys’s co-founders. He studied chemistry 

in his native New Zealand, and was a Commonwealth Scholar to the University 

of Oxford, where he completed a D. Phil. in Chemistry in 1984. Prior to cofounding 

MorphoSys in 1992, Dr Moroney held positions at the University of 

Cambridge, UK, at the University of British Columbia, Canada, and in the 

Chemistry Department of the ETH in Zurich, Switzerland. Subsequently he 

was an Associate in the Harvard Medical School, Boston, U.S.A., and an 

employee of ImmunoGen Inc, where he worked on the development of 

antibody-based cancer drugs. In 2002, Dr Moroney was awarded the 

Bundesverdienstkreuz am Bande (Cross of the Order of Merit of the Federal 

Republic of Germany) for his services to the biotechnology industry. 

–– 10 –– 

Mr Rajiv Narang 

Founder and Chief Executive Officer 

Erehwon Innovation Consulting Pvt Ltd 

Mr Narang’s passion and mission is to fuel the growth of innovative leaders 

and organisations. He has, over the last 17 years, developed a keen insight into 

‘what does it take for leaders and organisations to innovate and grow’. He has 

accomplished this through leading ‘Innovation for growth’ assignments with a 

number of organisations across different sectors. Some of his key clients 

include Novartis, Nokia, Development bank of Singapore, Bank of America, 

ESPN, International Flavours and Fragrances, Max New York Life, Unilever, 

Motorola, Bharti – Airtel and Marico Industries. 

He has also directly engaged in researching ‘Innovative leaders and 

organisations’ especially in Asia to develop fresh path-breaking ideas and 

insights and has been invited to speak at a number of national and 

international conferences. Some of these are The Strategic Innovators’ Forum 

at Barcelona, Delivering Effective Innovation at London, Unlocking Innovation – 

Convergence 2005 and 2006, The CII Innovation Summit, HRD Asia Congress 

in Singapore, The Economist Annual CEO’s Conclave, AIMA annual convention, 

FMCGs Conclave and CII’s India Governing Council. As a result of his 

experience in not only in business but social innovation, he has also been 

invited to consult with and guide large national and state level change and 

innovation projects. 

He is the innovation consultant to the ‘Innovation for India’ foundation and also 

a member of the managing council. 

Mr Gary Noon 


Aegate 

Gary Noon has 25 years’ experience in the pharmaceutical industry, fulfiling a 

number of roles including senior positions in general management, marketing, 

business development and sales in the US and Europe. He has worked for 

many of the world’s leading pharmaceutical companies such as Roche, Bristol 

Myers Squibb, Glaxo Wellcome and Warner Lambert and was President of IMS 

Health in the US. He has particular expertise in strategic marketing, supply 

chain management and product development and commercialisation. Before 

joining Aegate, Mr Noon was Senior Vice President and Head of 

Pharmaceuticals at Diversa Corporation.


Dr Jean-Pierre Paccaud 

Director of Business Development 

Drugs for Neglected Diseases Initiative (DNDi) 

Dr Jean-Pierre Paccaud is Director of Business Development at the Drugs for 

Neglected Diseases initiative (DNDi). In this role, he identifies business 

opportunities and expands DNDi’s network of partners and collaborators to 

facilitate the organization’s drug development efforts. 

DNDi is an independent, not-for-profit drug development initiative working to 

research and develop new and improved treatments for neglected diseases, 

such as leishmaniasis, human African trypanosomiasis, Chagas disease, and 

malaria. Prior to joining DNDi, Dr Paccaud founded Athelas SA, an antibacterial 

drug discovery company which recently merged with MerLion 

Pharmaceuticals Pte Ltd of Singapore. Dr Paccaud also served as Business 

Development Manager for OM Pharma; consulted for a number of 

biotechnology investment funds; and was tenured at the University of Geneva 

Medical School, where he established a medical research group. Dr Paccaud 

performed his post-doctoral studies at the University of California at Berkeley, 

after earning his PhD in clinical immunology at the University of Geneva 

School of Medicine. 

Ms Ann Pope 

Director, Markets and Projects – Goods 

Office of Fair Trading (OFT) 

Ann Pope is a Director at the Office of Fair Trading, working in the Goods 

Market Grouping, which is responsible for projects in pharmaceutical markets. 

She is an economist and has worked on a variety cases at the OFT. Her 

pharmaceuticals experience includes the removal of RPM on over-the-counter 

medicines, the Competition Act investigation into Genzyme, the market study 

on the PPRS and the current market study into medicines distribution. 

Mr Martyn Postle 

Director and Founder 

Cambridge Healthcare & Biotech Ltd 

Martyn Postle is a senior Director who has worked in and for the pharmaceutical 

industry for over 26 years. He held various management positions over a tenyear 

period with Eli Lilly in areas such as New Product Planning, Business 

Development and Marketing. He left Lilly to join Rorer Healthcare in the UK, 

where he was Strategic Planning Director and a member of their Executive 

Committee. He has been a Principal in both KPMG’s and Coopers & Lybrand’s 

consulting divisions where he led their respective pharmaceutical marketing and 

strategy consulting efforts. Prior to founding Cambridge Healthcare & Biotech 

has was a Senior Vice President of Cambridge Pharma Consultancy, where he 

led their Business and Marketing Strategy Group. He also spent 3 years as an 

investment banker with Dresdner Kleinwort Benson, where he was responsible 

for healthcare M&A projects based out of the bank’s London, Frankfurt and New 

York offices. Martyn has advised over 70 different pharmaceutical, biotech and 

healthcare companies in a diverse range of projects. He is also the Chair of the 

pharmaceutical sector group of the Taiwan Britain Business Council. 

–– 11 –– 

Dr Steven Powell 


Plethora Solutions Limited 

Steven Powell joined Plethora as Chief Executive Officer in 2004. Prior to this he 

was a director of the Gilde Biotechnology and Nutrition Fund, a pan-European 

venture capital fund focused on investments in early-stage companies. In addition 

to his private equity experience, Dr Powell has 20 years of experience in the 

pharmaceutical and life sciences sector, latterly as Chief Executive Officer of UK 

quoted biopharmaceutical company KS Biomedix plc until its acquisition by 

Xenova Group plc. He has worked in the pharmaceutical and life sciences 

industries in research and development, commercial and general management 

roles, initially for Beecham Pharmaceuticals (GSK) and subsequently with 

Whatman, Chiroscience, Celsis and Active Biotech. He has also helped to establish 

and finance a number of small life science businesses in a non-executive role. 

Dr Andy Richards 

Early Stage Biotechnology Investor 

Dr Andy Richards is a serial Biotechnology entrepreneur and business angel. 

He is currently a director of Vectura , Biowisdom, VASTox, Theradeas, Cancer 

Research Technology (commercial arm of CR-UK) Babraham Bioscience 

Technology, Aitua and is Chairman of Altacor and Pharmakodex. 

Dr Richards has a PhD in Chemistry and spent his early career with ICI (now 

AstraZeneca) and with PA Technology. He was a founder of Chiroscience and 

an executive director through to the merger with Celltech in 1999. Since that 

time he has been founding and investing in new biotechnology companies 

including several of those listed above as well as Arakis, Geneservice, 

Cambridge Biotechnology Ltd, Amedis Pharmaceuticals, Sirus Pharmaceuticals 

and Daniolabs all of which were recently sold. He is a director of the 

Bioindustry Association (BIA) a founder member of the Cambridge Angels, a 

founder investor in LibraryHouse and an advisor to Toscana Life Sciences. 

Mr Angus Russell 

Chief Financial Officer 

Shire plc 

Prior to joining Shire, Mr Russell worked for ICI, Zeneca and AstraZeneca for a 

total of 19 years. His last position was Vice President – Corporate Finance at 

AstraZeneca PLC, where he was responsible for financial input into M&A 

activities, management of tax, legal, and finance structure, investor relation’s 

activities and the management of various financial risks. Prior to this, he held a 

number of positions within ZENECA Group PLC and ICI including Group 

Treasurer, Group Investor Relations Manager, Strategic Planner, Marketing 

Manager and management accounting roles in manufacturing and R & D 

operations. Mr Russell is a chartered accountant, having qualified with Coopers 

& Lybrand, and is a member of the Association of Corporate Treasurers.


Speakers 

Mr Christian Siebert 

DG Enterprise and Industry 

European Commission 

Christian Siebert is Head of Unit in the European Commission, Enterprise and 

Industry Directorate-General, Unit “Competitiveness in the Pharmaceutical 

Industry and Biotechnology”. The activity of the unit includes the 

Pharmaceutical Forum, a follow-up to the “G10 Medicines” group’s policy 

recommendations on access of patients to medicines and on improved 

conditions for innovation in the European pharmaceuticals industry. The unit 

also contributes to the development/implementation of the European 

Commissions’ policy document and action plan “Life Sciences and 

Biotechnology – a Strategy for Europe”. 

He joined the European Commission in 1991 and held previous positions in the 

Enterprise/Industry Department, dealing with biotechnology, the food 

industry, co-operation with Central/Eastern Europe and with GATT/WTO 

matters. He also has been Assistant to the Director-General for Industry. 

Mr Siebert graduated (M.A.) in Political Science and Economics at the 

University of Mainz (Germany), before completing post-graduate studies at 

the College of Europe (Bruges, Belgium). 

Mr Shinichi Tamura 


Sosei Group Corporation 

Mr Tamura is co-founder of Sosei Company Limited and has been its Chief 

Executive Officer since 1990, and since October 2006 Chief Executive Officer of 

Sosei Group Corporation. From 1988 to 1991, Mr Tamura was the Representative 

Director (Chief Executive Officer) for Genentech Ltd and was in charge of the 

Japanese operations for Genentech Inc. From 1986, he had been advisor for 

Genentech, IDEC, Geron and Kissei, among others, for various periods of time. 

Prior to that, he has held various positions in Planning and Development at 

Fujisawa (Astellas) from 1978 to 1986. Mr Tamura has an MS in Biochemistry 

from the University of Tokyo, in addition to studying Cultural Anthropology. 

Mr Brian Thornley 

Chief Operations Officer 

Aegate 

Brian Thornley joined Aegate in August 2007 as Chief Operations Officer, 

bringing with him many years experience in the pharmaceutical industry. 

Previously, Mr Thornley was Director of European Supply Chain for GSK where 

he was responsible for managing the supply chain from 25 factories across 44 

countries in Europe. At GSK, he was also responsible for supporting European 

sales of £4.2Bn. 

Mr Thornley is an active member of the European Federation of 

Pharmaceutical Industry and Associations (EFPIA)’s Distribution and Supply 

Chain Committee. 

–– 12 –– 

Mr Robert Wessman 

President and Chief Executive Officer 

Actavis Group 

Robert Wessman joined the board in April 2007. He has been the President 

and Chief Executive Officer of Actavis since 2002, following the merger with 

Delta, where he had served as Chief Executive Officer since 1999. Under Mr 

Wessman’s leadership, Actavis has experienced phenomenal growth, from 

being a small domestic company in Iceland to becoming one of the largest 

companies in the generics industry. A business administration graduate and 

lecturer at the University of Iceland, he worked previously at Icelandic 

transportation company Samskip, advancing to the post of Chief Executive 

Officer in Germany. Mr Wessman is also a Board member of the Iceland 

Chamber of Commerce. 

Mr Dan Zabrowski 

Global Head Pharma Partnering 

Roche 

Dan Zabrowski is the Global Head of Pharma Partnering. In this role, Dr 

Zabrowski oversees Roche’s world class network of strategic alliances with 

biotech companies and creates new alliances for the future. From 2002 to 

2007, Dr Zabrowski served as the Global Head of Pharma Development 

Operations and Vice President of Pharma Development, Nutley for Hoffmann- 

La Roche, Inc. This group is responsible for management of all global clinical 

trials for Roche. 

Prior to this assignment, Dr Zabrowski was Global Head, Drug Regulatory 

Affairs for Roche Pharma Division for 5 years. Dr Zabrowski joined Roche in 

1995 following the company’s acquisition of Syntex, Inc, where he held a 

variety of positions in Regulatory Affairs. Prior to that assignment, he led 

Regulatory Affairs in North America for Fujisawa Pharmaceutical Company. Dr 

Zabrowski started his regulatory career at Searle. Before moving to the 

regulatory field, Dr Zabrowski conducted drug discovery research at Searle in 

serotonin receptor modulators. 

Dr Zabrowski received a BA degree in Chemistry from Saint Louis University 

and a PhD in Organic Chemistry from Indiana University – Bloomington.


In association with 

Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms, and their respective 

subsidiaries and affiliates. Deloitte Touche Tohmatsu is an organisation of member firms around the world devoted to 

excellence in providing professional services and advice, focused on client service through a global strategy executed 

locally in nearly 140 countries. 

With access to the deep intellectual capital of approximately 150,000 people worldwide, Deloitte delivers services in four 

professional areas-audit, tax, consulting, and financial advisory services – and serves more than 80 percent of the world’s 

largest companies, including 85 percent of the Fortune Global 500® life sciences and health care companies, as well as 

large national enterprises, public institutions, locally important clients, and successful, fast-growing global companies. 

www.deloitte.com 

–– 13 ––


Sponsors 

Almirall is an international pharmaceutical company that researches, develops, manufactures and commercialises 

innovative proprietary drugs and those under licence in order to improve people’s health and wellbeing. Almirall focuses its 

research resources in the areas of asthma, COPD (Chronic Obstructive Pulmonary Disease), psoriasis, rheumatoid arthritis 

and multiple sclerosis. 

Almirall is headquartered in Barcelona, Spain. The company employs approximately 3,000 people across the world, 30% 

of whom are based outside Spain. The company markets its drugs in more than 80 countries including the US and Japan, 

and has five affiliates in Europe (Germany, Belgium, France, Italy and Portugal) as well as one in Latin America (Mexico). 

2006 IMS figures show that Almirall is the third largest pharmaceutical company in Spain (behind Pfizer and Novartis) and 

is one of the top 40 largest pharmaceutical companies in Europe. The company was floated on the Spanish stock 

exchange on 20 June 2007. 

www.almirall.es 

Warburg Pincus has been a leading private equity investor since 1971. The firm currently has more than $20 billion of 

assets under management. Since inception, Warburg Pincus has invested more than $26 billion in more than 575 

companies in 30 countries across a range of nine industry sectors. Healthcare is one of the firm’s core areas for 

investment globally, with members of our healthcare team focused on biotechnology, specialty pharmaceuticals, medical 

devices and healthcare services. 

Our current European healthcare portfolio includes Archimedes Pharma, Eurand, Euromedic, ProStrakan and Tornier. The 

firm has invested over $4 billion in healthcare globally, of which over $1 billion has been invested in Europe. For more 

information, visit: 

www.warburgpincus.com 

–– 14 ––


Roundtable hosts 

Aegate provides a unique patient safety service that supports pharmacists and pharmaceutical manufacturers in the 

authentication of medicines. The service works in real time at the point of dispensing to ensure that patients do not 

inadvertently receive substandard products. 

Once installed the service provides a direct, two-way communications network which links the pharmaceutical 

manufacturer and the pharmacist. This network acts as a protective mechanism by providing patient safety messages 

direct to pharmacists at the time when they are interacting with the product. This additional layer of security supports 

pharmacists by providing information on the specific pack being dispensed to ensure that counterfeit and stolen 

medicines, out-of-date products or product recalls are inadvertently dispensed. In addition to providing information on the 

status of the pack of medicine being dispensed, the pharmacist can be provided with supplementary information about 

the medicine. This information supports the pharmacist in ensuring that patients take their medication correctly getting 

the full benefit of their treatment. 

Aegate's service authenticates medicines using an identification technique known as mass or unique serialisation, a 

method by which items are identified by a unique individual number. Typically, these are applied by pharmaceutical 

manufacturers. The most commonly used technologies for unique serialisation are different types of barcodes, 1D or 2D, or 

RFID, Aegate can work with any type of code. The Aegate service is integrated into pharmacy software packages so that 

pharmacists experience seamless dispensing. 

Aegate's has been operational in Belgium since 2006 and launched in Greece this year. Aegate has also adapted their 

technology to meet the needs of the developing world, by using a mobile phone and, a simple, cost effective 2D barcode they 

can increase patient safety in a broad range of environments. Aegate has further plans for growth across Europe in 2008. 

www.aegate.com 

Operating in more than 100 countries, IMS Health is the world’s leading provider of market intelligence to the 

pharmaceutical and healthcare industries. With $2.0 billion in 2006 revenue and more than 50 years of industry 

experience, IMS offers leading-edge business intelligence products and services that are integral to clients’ day-to-day 

operations, including portfolio optimisation capabilities; launch and brand management solutions; sales force effectiveness 

innovations; managed care and over-the-counter offerings; and consulting and services solutions that improve ROI and the 

delivery of quality healthcare worldwide. Additional information is available at: 

www.imshealth.com 

–– 15 ––


Supporting partners 

–– 16 –– 

Established in 1989, the BIA (BioIndustry Association) exists to encourage 

and promote a financially sound and thriving bioscience sector within the UK 

economy and concentrates its efforts on emerging enterprise and the related 

interests of companies with whom such enterprise trades. 

With over 300 members, the BIA supports a wide range of sectors, majoring 

on the human health benefits of the technology and represents the interests of 

these innovative companies to a broad section of stakeholders from patient 

groups to politicians, advancing its members interests both within the UK and 

internationally to create a healthy UK bioscience sector which benefits society. 

www.bioindustry.org 

BioPharm Insight provides mission critical information to life science 

professionals worldwide. Our focus is on providing the most up-to-date, 

forward looking insight to help our clients capitalize upon opportunities in their 

business. Through our global network of journalists and research analysts, we 

provide analysis, research, and data that enables our clients to make faster, 

better decisions. Our on-line databases include information on: Clinical Trials, 

Investigational and Approved Drugs, Licensing Deals, Pharmaceutical Sales 

and Projections, Medical Devices, and Management Contacts. 

www.biopharminsight.com 

Bloomberg is the leading source of data, news and analytics for corporations, 

news organizations, financial professionals and individuals around the globe. 

The BLOOMBERG PROFESSIONAL ® service and BLOOMBERG NEWS ® 

services provide real-time and historical pricing, indicative data, reporting, 

analytics, multimedia events and electronic communications to Bloomberg 

clients in more than 125 countries, 24 hours a day. 

www.bloomberg.com 

European Biopharmaceutical Enterprises (EBE) is the European trade 

association that represents biopharmaceutical companies of all sizes 

operating in Europe. It was established in 2000 as a specialised group of 

EFPIA and is headquartered in Brussels. Membership in EBE is open to all 

companies using biotechnology to discover, develop and bring new medicinal 

products to market. EBE’s focus on the biopharmaceutical sector provides 

targeted and results-oriented support for its members. It has developed a 

wide range of activities and services for members, embracing policy advocacy, 

regulatory intelligence, strategic communications, business development, 

networking, education and training. 

EBE has also developed specific programmes to address technical matters 

(e.g. biotech manufacturing standards and good practices) and cover growing 

niche markets (e.g orphan medicinal products). 

www.ebe-biopharma.org 

To serve the advancement of drug research, development and effective use by 

enhancing the efficiency of communication among pharmaceutical 

researchers and decision-makers, and by providing innovative solutions to 

their information needs. Published by Informa Healthcare (publisher of Scrip, 

Biotechniques and the Taylor & Francis journals), the Expert Opinion series 

was developed in response to discussions with a wide range of decisionmakers 

in pharma and biotech companies. The frequently stated need was for 

systematic and authoritative analysis of all available information on patents, 

drug discovery, drugs in R&D and those on the market. 

www.expertopin.com


–– 17 –– 

The leading online biopharmaceutical resource. InPharm provides industry 

executives with tailored information including: 

Pharmafocus – A monthly newspaper-style publication for the pharmaceutical 

industry. Featuring exclusive news on the latest developments in marketing 

and R&D, and the changing NHS and regulatory environment. 

InPharmjobs.com – Provides a comprehensive specialist online recruitment 

service for the pharmaceutical industry. One of the most widely used online 

recruitment sites dedicated to the sector. 

Pharmafile – The leading directory of specialist suppliers for people working in 

the pharmaceutical and related industries. Published every six months, 

Pharmafile is the most up to date directory of the sector available anywhere. 

www.inpharm.com 

Pharmaceutical Executive Europe magazine is the leading strategy-based, 

business management publication for senior executives, corporate strategists 

and sales and marketing leaders in the European pharmaceutical industry. 

Tackling strategic business and marketing issues, Pharm Exec Europe 

provides complete high-quality analysis, opinion and industry news on critical 

trends and developments; sales and marketing strategies; corporate policy, 

management and branding; research and development; legislation; finance; 

new technologies and much more. 

Pharm Exec Europe is the indispensable read for senior pharmaceutical 

executives who need to stay informed, innovative and ahead of the game. 

www.pharmexeceurope.com 

Pharmaprojects tracks every significant new drug under development from 

lead through early preclinical study and clinical phases, to launched or 

discontinued status – and beyond. At the same time, we closely monitor 

company activity and therapeutic developments. The results of this 

intelligence gathering, harnessed to Pharmaprojects' powerful functionality, 

means you can use our database to focus on what's critical to your business – 

reliable competitor intelligence. 

In addition, you can use Pharmaprojects when benchmarking your 

competitors’ R&D activity and performance, to assess potential business 

partners, identify in/out licensing opportunities and analyse industry trends, 

giving you the means to drive confident R&D strategy and decision-making. 

www.pharmaprojects.com/research_development_analysis 

Pharmawire publishes real-time news and data on the most price sensitive 

issues in the global pharmaceutical market. Built for financial professionals, 

Pharmawire covers product approvals, litigation, licensing deals and M&A. 

Pharmawire is a part of The Mergermarket Group, a division of the Financial 

Times Group. 

www.pharmawire.com 

Whether you’re an industry leader or a rising star you need Scrip’s unique mix 

of succinct, straight-forward coverage of the issues that matter across the 

pharma industry. No other publication aids such complete industry 

knowledge. No other publication provides its coverage in such a digestible 

style. And no other publication has provided such indispensable information to 

your industry for over thirty years. That’s why pharmaceutical executives at all 

levels, in all departments, rely on Scrip World Pharmaceutical News to help 

them achieve both company and individual success. 

www.pjbpubs.com/scrip


Organisers 


Global Conferences & Events 

Financial Times Conferences Global Conferences & Events 

has an international reputation for quality, agenda setting 

programmes and the ability to attract speakers of the 

highest calibre. Our events offer senior executives the 

opportunity to attend proven forums and debates on key 

issues, whilst providing a unique opportunity to network 

with high-level peers and potential clients. 

Our annual conferences cover a wide range of key 

industry sectors, and our bespoke forums allow the client 

to work with FT conferences in the development of 

themes and format. The FT Global Awards programme 

has a reputation for excellence and the judging panels are 

drawn from renowned experts in the fields of business, 

commerce and industry as well as senior editorial figures 

from the Financial Times. 

www.ftconferences.com 

Financial Times Conferences 

Sponsorship Opportunities 

For more information, please contact 

Toufique Khan: 

Telephone: +44 (0)20 7873 3260 

Email: toufique.khan@FT.com 

Delivering results for 

over 35 years


Make your business 

a model of success 

Fine tune to create the ultimate machine 

Modern science refers to the human body’s intricate systems as the ultimate machine. The Life Sciences and Health Care practices 

of Deloitte Touche Tohmatsu (DTT) member firms have honed their experience working with the world’s largest life sciences companies 

to help you fine tune your intricate processes and operate as smoothly as nature’s example. Our member firms’ multi–functional teams 

have the tools and comprehensive experience to help shape new strategies, improve operations, and achieve greater financial efficiencies 

as you strive to transform your organization into a model of success. 

For more information, contact: 

DTT – Life Sciences and Health Care 

Robert Go 

Deloitte Consulting LLP (US) 

+1 313 324 1191 

rgo@deloitte.com 

Europe, Middle East and Africa 

Stuart Henderson 

Deloitte & Touche LLP (United Kingdom) 

+44 1223 259392 

stuhenderson@deloitte.co.uk 

United Kingdom 

Simon Hammett 

Deloitte & Touche LLP (United Kingdom) 

+44 20 7303 6402 

shammett@deloitte.co.uk 

www.deloitte.com/lifesciences 

About Deloitte 

Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms, and their respective subsidiaries and affiliates. Deloitte Touche Tohmatsu is an organization of member firms 

around the world devoted to excellence in providing professional services and advice, focused on client service through a global strategy executed locally in over 140 countries. With access to the deep 

intellectual capital of approximately 150,000 people worldwide, Deloitte delivers services in four professional areas—audit, tax, consulting, and financial advisory services—and serves more than 80 percent 

of the world’s largest companies, as well as large national enterprises, public institutions, locally important clients, and successful, fast-growing global companies. Services are not provided by the Deloitte 

Touche Tohmatsu Verein, and, for regulatory and other reasons, certain member firms do not provide services in all four professional areas. 

As a Swiss Verein (association), neither Deloitte Touche Tohmatsu nor any of its member firms has any liability for each other’s acts or omissions. Each of the member firms is a separate and independent 

legal entity operating under the names “Deloitte,” “Deloitte & Touche,” “Deloitte Touche Tohmatsu,” or other related names. 

Copyright © 2007 Deloitte Development LLC. All rights reserved.


JSN0013A 

CS5766 

Find out what makes 

stand out 

Why not take a free trial today and see how 

Scrip information differs from the rest 

www.scripnews.com/trial


Notes 

–– 21 ––


Notes 

–– 22 ––


–– 23 ––


Notes 

–– 24 ––


–– 25 ––


Notes 

–– 26 ––

1341 PharmaBio Delegate Booklet 28/11/07 14:42 Page 27


www.ftpharmabiotech.com

1341 PharmaBio Delegate Booklet

Create successful ePaper yourself

Delete template?

Save as template?